Quality-of-Life Measurements Versus Disease Activity in Systemic Lupus Erythematosus

Kiani, Adnan N.; Petri, Michelle

doi:10.1007/s11926-010-0114-1

Cited by 63 publications

(53 citation statements)

References 75 publications

(98 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…22 Another related cause is fibromyalgia, which we did not study, which could be related to quality of life and fatigue. 23 The lack of data on other factors like fibromyalgia, anemia and thyroid functions is a limitation of this study. The higher fatigue (lower FACIT-F score) in patients on higher doses on oral steroids is interesting and may due to a direct effect of chronic high-dose steroids or it may indicate residual disease activity.…”

Section: Discussionmentioning

confidence: 91%

The relationship of fatigue with quality of life in patients with systemic lupus erythematosus having low disease activity

Mishra¹,

Dhir²,

Aggarwal³

2015

Indian Journal of Rheumatology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 91%

The relationship of fatigue with quality of life in patients with systemic lupus erythematosus having low disease activity

Mishra¹,

Dhir²,

Aggarwal³

2015

Indian Journal of Rheumatology

View full text Add to dashboard Cite

“…HRQoL is compromised in SLE patients as a result of the disease itself but frequently also due to the coexistence of aggravating factors, especially fatigue, pain and depression (reviewed in62 63). Thus, cross-sectional studies have reported weak inverse associations between HRQoL and measures of SLE activity64–66 and damage64 65 67–69 (correlation coefficients typically in the range of −0.20 to −0.52).…”

Section: Resultsmentioning

confidence: 99%

Treat-to-target in systemic lupus erythematosus: recommendations from an international task force

et al. 2014

View full text Add to dashboard Cite

The principle of treating-to-target has been successfully applied to many diseases outside rheumatology and more recently to rheumatoid arthritis. Identifying appropriate therapeutic targets and pursuing these systematically has led to improved care for patients with these diseases and useful guidance for healthcare providers and administrators. Thus, an initiative to evaluate possible therapeutic targets and develop treat-to-target guidance was believed to be highly appropriate in the management of systemic lupus erythematosus (SLE) patients as well. Specialists in rheumatology, nephrology, dermatology, internal medicine and clinical immunology, and a patient representative, contributed to this initiative. The majority convened on three occasions in 2012-2013. Twelve topics of critical importance were identified and a systematic literature review was performed. The results were condensed and reformulated as recommendations, discussed, modified and voted upon. The finalised bullet points were analysed for degree of agreement among the task force. The Oxford Centre level of evidence (LoE, corresponding to the research questions) and grade of recommendation (GoR) were determined for each recommendation. The 12 systematic literature searches and their summaries led to 11 recommendations. Prominent features of these recommendations are targeting remission, preventing damage and improving quality of life. LoE and GoR of the recommendations were variable but agreement was >0.9 in each case. An extensive research agenda was identified, and four overarching principles were also agreed upon. Treat-to-target-in-SLE (T2T/SLE) recommendations were developed by a large task force of multispecialty experts and a patient representative. It is anticipated that 'treating-to-target' can and will be applicable to the care of patients with SLE.

show abstract

“…Previous studies have also suggested that disease activity has an impact on HRQoL. 9,10 The prevalence of fatigue among patients with SLE is high and is present in up to 90% of patients. 18 In this study, the mean value of fatigue among all SLE patients was 6.1, comparable to results from other studies including patients with SLE.…”

Section: Discussionmentioning

confidence: 99%

Drivers of cost and health-related quality of life in patients with systemic lupus erythematosus (SLE): a Swedish nationwide study based on patient reports

Bexelius¹,

Wachtmeister

Skare

et al. 2013

Lupus

View full text Add to dashboard Cite

The objective of this paper is to investigate drivers of cost and health-related quality of life (HRQoL) related to disease activity and fatigue among patients with systemic lupus erythematous (SLE). A questionnaire was sent to members of a patient organization with a self-reported diagnosis of SLE, requesting information on demographics and disease characteristics, medications, resource utilization, informal care, loss of productivity, fatigue and HRQoL in relation to SLE. Mean annual costs per patient were estimated from a societal perspective. HRQoL was measured through EQ-5D and fatigue was measured through a 10 cm VAS scale. Patient-reported disease activity was measured through the Systemic Lupus Activity Questionnaire (SLAQ) and corticosteroid dose. Drivers of costs and HRQoL were analyzed through regression analysis. A total of 339 patients out of 737 returned the questionnaire. Mean age was 55; 94% were female. The mean HRQoL measured through the five-item EQ-5D instrument was 0.64 and total costs were estimated at €22,594 (direct costs €7818; indirect costs €14,776). Disease activity, fatigue and corticosteroid doses had a statistically significant impact on costs and HRQoL. This study demonstrates that Swedish patients with SLE have low HRQoL and incur high societal costs and that are both associated with and most likely driven by disease activity, fatigue and corticosteroid use.

show abstract

Quality-of-Life Measurements Versus Disease Activity in Systemic Lupus Erythematosus

Cited by 63 publications

References 75 publications

The relationship of fatigue with quality of life in patients with systemic lupus erythematosus having low disease activity

The relationship of fatigue with quality of life in patients with systemic lupus erythematosus having low disease activity

Treat-to-target in systemic lupus erythematosus: recommendations from an international task force

Drivers of cost and health-related quality of life in patients with systemic lupus erythematosus (SLE): a Swedish nationwide study based on patient reports

Contact Info

Product

Resources

About